Nimenrix is a vaccine used to protect individuals against invasive diseases caused by Neisseria meningitidis, a bacterium responsible for meningitis and septicemia, which can be life-threatening. Specifically, Nimenrix targets four major groups of this bacterium: A, C, W-135, and Y. It is a conjugate vaccine, meaning it links the polysaccharide antigens from these bacteria to a protein carrier to enhance the immune response. This vaccine is administered via injection and is recommended for individuals from the age of 6 weeks and older, including adults, to provide long-term protection against these dangerous strains of meningococcal bacteria. Nimenrix is particularly important for travelers to areas where meningococcal disease is common, as well as for people in close living situations, such as college dormitories, where the disease can spread more easily.